Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Nov 2017
Randomized Controlled Trial Multicenter StudyEfficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is efficacious in treating moderate-to-severe plaque psoriasis through 60 weeks. ⋯ Ixekizumab is well tolerated and demonstrates persistent efficacy through 108 weeks.